Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway

Nuvectis Pharma, Inc.

2025-Q3 EPS reported -$1.01

Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.
Net loss $7.5M (Q3 2025) vs $4.2M (Q3 2024); increase driven by $2.0M NXP900 milestone expense.
R&D expenses $5.8M (Q3 2025) vs $2.8M (Q3 2024), reflecting clinical progress.
NXP900 Phase 1b single-agent portion initiated; combination arm expected by year-end 2025.
Phase 1a dose escalation and drug-drug interaction study completed with pharmacodynamic responses at clinically relevant doses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.